Clinical trial
Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
NCT07617272
Study timeline
Study start (actual)2025-11-09Date precision: day
Registry last updated2026-06-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancer (Adenocarcinoma)unresolved
Interventions
DarolutamideDRUG · verified · RxNorm: darolutamide
Radical prostatectomyPROCEDURE
Sponsors & collaborators
Region Stockholmlead sponsor
Sahlgrenska University Hospitalcollaborator
Philips Intellectual Property & Standardscollaborator
OHMX.biocollaborator
European Unioncollaborator
Bayercollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07617272 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.